Clinical Trials- Neuro/Brain

 DISEASE SITE  TITLE  PHASE  CONTACT  LOCATION
 Glioblastoma Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus
Bevacizumab Alone as Treatment for Recurrent Glioblastoma (RTOG 1205)
 II Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
 Nebraska Methodist Hospital
Omaha, NE
 Glioblastoma  Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients with
Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiform
(Sara Cannon CNS 13)
 I/II Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
 Nebraska Methodist Hospital
Omaha, NE
 Glioblastoma or Gliosarcoma Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or  Without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma
(RTOG 1122)
 II Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
 Nebraska Methodist Hospital
Omaha, NE
Anaplastic Glioma  "Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with
Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (N0577)" 
 II

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

--------------

Marcia Grafe    402-483-2827           mgrafe@lmep.com

Missouri Valley Cancer Consortium, Omaha, NE;

Nebraska Cancer Research Center/ Lincoln Medical Education Partnership Lincoln, NE

 Glioblastoma  "Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with
Bevacizumab in Recurrent Glioblastoma (N0872)" 
 I

Natasha Wilson, nwilson@mvcc.cc

402-991-8070 x203

-------------------------------Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or Rose, Hoyt

------------------------------------

Marcia Grafe  402-483-2827      mgrafe@lmep.com      

----------------------

Missouri Valley Cancer Consortium, Omaha, NE;  

 Nebraska Medical Center, Omaha NE;

Nebraska Cancer Research Center/ Lincoln Medical Education Partnership Lincoln, NE;

 Brain Mets  "Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in
Patients with One to Three Cerebral Metastases (N0574)
Note: SRS approval at Immanuel location only" 
 III

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

--------------------------

 Marcia Grafe        402-483-2827  mgrafe@lmep.com

---------------------

Missouri Valley Cancer Consortium, Omaha, NE;

Nebraska Cancer Research Center/ Lincoln Medical Education Partnership Lincoln, NE

 Glioma, low grade  Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas (E3F05)  III

Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831

-------------------- 

Natasha Wilson, nwilson@mvcc.cc

402-991-8070 x203

--------------------

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or Amy Filler-Katz

-------------------

 

Marcia Grafe   402-483-2827  mgrafe@lmep.com

 Nebraska Methodist Hospital
Omaha, NE;  

Missouri Valley Cancer Consortium, Omaha, NE;

 

Nebraska Medical Center, Omaha, NE;

Nebraska Cancer Research Center/ Lincoln Medical Education Partnership Lincoln, NE

 Brain Mets   A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease  (N107C)  III

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or Amy Filler-Katz

 Nebraska Medical Center, Omaha NE
 Teratoid/ Rhabdoid CNS  Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation (ACNS0333)  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or Angie Boettner

 Nebraska Medical Center, Omaha NE
Neuroblastoma  A Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue  (ANBL0032 )  III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu orTamra Olson

 Nebraska Medical Center, Omaha NE
Anaplastic Glioma Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial  III

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or  Amy Filler-Katz

 Nebraska Medical Center, Omaha NE

Medulloblastoma

PNET

 Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients (ACNS0332; CHMC IRB #545-0907)    

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or Nancy Berounsky

 Nebraska Medical Center, Omaha NE
Glioma, high grade  A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation or Temozolomide and Local Irradiation or Bevacizumab (IND# 7921) and Local Irradiation Followed By Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas (ACNS0822; UNMC 651-11)  II/III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu orTamra Olson

 Nebraska Medical Center, Omaha NE
Ependymoma  Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years (Version date 2/10/2010 (ACNS0831; Children's 001-11)  III

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or  Angie  Boettner

 Nebraska Medical Center, Omaha NE
Glioblastoma  Everolimus, Temozolomide, and Radiation Therapy in Treating Patients with Newly diagnosed Glioblastoma Multiforme (RTOG 0913  I/II  Michaela Sherbeck - michaelasherbeck@catholichealth.net  Good Samaritan Cancer Center, Kearney, NE
 Glioblastoma  An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GMCSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-Positive Glioblastoma  III  

Lindsay Clements, RN, BSN, OCN, CCRP

lindsayc@leadingcancercare.com

402-327- 7363

 Southeast Nebraska Cancer Center, Lincoln, NE

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software